Article

Highest Medication Costs, Premium Increases Highlight AJPB Week in Review

Author(s):

Davy James, Managing Editor

Top news of the week from The American Journal of Pharmacy Benefits.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Chronic kidney disease (CKD) -- Image credit: Kiattisak | stock.adobe.com
June 12th 2025

Finerenone and Empagliflozin Outperform Either Treatment Alone in Patients With CKD

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Op-Ed: Expand Patient Choice to Lower Medication Costs
June 6th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs

Colin Edgerton, MD
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
June 6th 2025

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Gillian McGovern, Associate Editor
Injectors and dosing pens for subcutaneous injection of antidiabetic medications or a anti-obesity medication lying on a pink backdrop, top view. Medicine and weight loss, concept.
June 4th 2025

Recombinant Human Hyaluronidase-Facilitated SCIg Sustains Clinical Remission in Idiopathic Inflammatory Myositis

Luke Halpern, Assistant Editor